IMC Chicago’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $81.7M | Sell |
375,600
-22,200
| -6% | -$4.92M | 0.03% | 350 |
|
|
2025
Q4 | $90.9M | Sell |
397,800
-142,300
| -26% | -$32.4M | 0.03% | 313 |
|
|
2025
Q3 | $125M | Buy |
540,100
+157,200
| +41% | +$32M | 0.05% | 230 |
|
|
2025
Q2 | $71.1M | Sell |
382,900
-40,400
| -10% | -$7.51M | 0.03% | 308 |
|
|
2025
Q1 | $88.7M | Sell |
423,300
-122,300
| -22% | -$23.8M | 0.05% | 194 |
|
|
2024
Q4 | $97M | Buy |
545,600
+167,500
| +44% | +$30.8M | 0.05% | 213 |
|
|
2024
Q3 | $74.7M | Sell |
378,100
-5,000
| -1% | -$933K | 0.04% | 224 |
|
|
2024
Q2 | $65.7M | Buy |
383,100
+162,300
| +74% | +$26.9M | 0.04% | 234 |
|
|
2024
Q1 | $40.2M | Sell |
220,800
-47,400
| -18% | -$8.17M | 0.02% | 294 |
|
|
2023
Q4 | $41.6M | Buy |
268,200
+46,500
| +21% | +$6.78M | 0.03% | 294 |
|
|
2023
Q3 | $33M | Sell |
221,700
-61,400
| -22% | -$9.01M | 0.03% | 272 |
|
|
2023
Q2 | $38.1M | Buy |
283,100
+48,100
| +20% | +$7.05M | 0.04% | 241 |
|
|
2023
Q1 | $37.5M | Sell |
235,000
-24,000
| -9% | -$3.67M | 0.04% | 217 |
|
|
2022
Q4 | $41.9M | Sell |
259,000
-7,000
| -3% | -$1.07M | 0.07% | 185 |
|
|
2022
Q3 | $35.7M | Buy |
266,000
+9,000
| +4% | +$1.29M | 0.05% | 181 |
|
|
2022
Q2 | $39.4M | Buy |
257,000
+69,100
| +37% | +$10.6M | 0.06% | 169 |
|
|
2022
Q1 | $30.5M | Sell |
187,900
-74,400
| -28% | -$10.8M | 0.03% | 260 |
|
|
2021
Q4 | $35.5M | Sell |
262,300
-15,800
| -6% | -$1.87M | 0.03% | 264 |
|
|
2021
Q3 | $30M | Buy |
278,100
+98,700
| +55% | +$11.3M | 0.03% | 271 |
|
|
2021
Q2 | $20.2M | Buy |
179,400
+6,500
| +4% | +$732K | 0.02% | 329 |
|
|
2021
Q1 | $18.7M | Sell |
172,900
-16,500
| -9% | -$1.76M | 0.03% | 308 |
|
|
2020
Q4 | $20.3M | Buy |
189,400
+60,900
| +47% | +$5.85M | 0.03% | 275 |
|
|
2020
Q3 | $11.3M | Buy |
128,500
+1,800
| +1% | +$169K | 0.02% | 297 |
|
|
2020
Q2 | $12.4M | Sell |
126,700
-73,900
| -37% | -$6.51M | 0.03% | 230 |
|
|
2020
Q1 | $15.3M | Sell |
200,600
-42,000
| -17% | -$3.58M | 0.03% | 160 |
|
|
2019
Q4 | $21.5M | Buy |
242,600
+53,200
| +28% | +$4.42M | 0.06% | 121 |
|
|
2019
Q3 | $14.3M | Sell |
189,400
-88,300
| -32% | -$6.05M | 0.04% | 140 |
|
|
2019
Q2 | $20.2M | Buy |
277,700
+177,600
| +177% | +$14M | 0.07% | 103 |
|
|
2019
Q1 | $8.07M | Buy |
100,100
+55,000
| +122% | +$4.5M | 0.03% | 172 |
|
|
2018
Q4 | $4.16M | Buy |
+45,100
| New | +$3.97M | 0.01% | 239 |
|
Other funds holding ABBV
VCM
VPM
IMC Chicago's ABBV Position: Q1 2026 in Review
IMC Chicago sold out of AbbVie (ABBV) in Q1 2026, closing a stake of 91,287 shares — an estimated $20.2M sold.
IMC Chicago first reported a position in ABBV in Q4 2019 and held it in 10 quarters. The position peaked at $20.9M in Q4 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- IMC Chicago reported no remaining AbbVie position as of Q1 2026 after selling out during the quarter.
- IMC Chicago sold 91,287 AbbVie shares in Q1 2026, an estimated $20.2M.
- IMC Chicago first reported a position in AbbVie in Q4 2019 and held it in 10 quarters.
- IMC Chicago's AbbVie position peaked at $20.9M in Q4 2025.
- 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on IMC Chicago's 13F filing for Q1 2026, filed 5 May 2026.